Monday, September 14, 2026

WORLD WAR III TRIGGER : Ten Nuclear Daggers Aimed At The Heart Of The Pacific

North Korea launched an unidentified projectile towards the East Sea, marking its first show of force in six weeks, heightening tensions.

How Korean Startups Are Expanding to Singapore and India: A 2026 Guide

Korean startups are expanding globally, reaching beyond the U.S. and Japan to Singapore and India.

Why Quick Weight Loss Can Lead to Serious Health Issues!

Doctors warn that even simple weight loss methods can potentially harm your body. They advise getting a health checkup before starting.

Tag: CDMO

Lotte Biologics at DCAT Week 2026: Unveiling Strategic Collaborations in Global CDMO

Lotte Biologics will attend DCAT Week in New York to pursue global CDMO partnerships and showcase its production capabilities.

Samsung Biologics CEO John Rim Poised for Third Term: What This Means for the Global CDMO Market in 2026

John Rim of Samsung Biologics aims for a third term, leading record growth and expansion into next-gen therapies amid global challenges.

Samsung Biologics: How a 56 Billion USD CDMO Leader is Shaping the Future of Biopharmaceuticals

Samsung Biologics is evolving as a leading CDMO, targeting a production capacity of 1.32M liters by 2030 after its spin-off from Bioepis.

ST Pharm’s Record Growth: How RNA-Based Therapies Are Transforming the CDMO Market in 2026

ST Pharm reports record growth in oligonucleotide CDMO, driven by rising demand for RNA-based treatments for chronic diseases.

Samsung Biologics Unveils Three-Pillar Growth Strategy: How Capacity, Portfolio, and Global Expansion Shape 2026

Samsung Biologics outlines a growth strategy focused on production, portfolio, and global expansion to enhance its CDMO position.

GAME OVER: Samsung Biologics Declares War With ‘ExellenS’—A Standard That Kills All Biotech Competition

Samsung Biologics launches ExellenS in Europe, enhancing biopharmaceutical production with standardized quality and efficiency.

Top News

- Our Sponsors Ad -

Follow us